BCMA Targeted CAR T-cells
Phase 1Cell therapy
BCMA Targeted CAR T-cells is one of 39 biologic programs targeting Multiple Myeloma. It is currently in Phase 1.
1
Indications
3
Total Trials
2
Active Trials
38
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
259 competitors in Multiple Myeloma
#DrugCompanyPhaseTrials
1TALVEY
Johnson & JohnsonPhase 3
Venclexta
AbbViePhase 3
Keytruda
Merck & Co.Phase 3
Opdivo
Bristol-Myers SquibbPhase 3
Xpovio
KKaryopharm Therapeutics Inc
Phase 3
Vepesid
AAvyxa
Phase 3
Elranatamab
PfizerPhase 3
Cytosar
TevaPhase 3
Busulfex
Akero TherapeuticsPhase 3
BLENREP
GGlaxo Dba Glaxosmithkline
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Multiple Myeloma3 trials
Study of SYS6020 in BCMA-positive Multiple Myeloma
Not yet recruiting·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·Phase 1·NCT06359509·10 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for BCMA Targeted CAR T-cells. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Cell therapy[2]
- Highest Phase
- Phase 1[1]
- Company
- ZZhejiang University